These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 34478148)

  • 21. The Immunogenicity of Biologic Therapies.
    Garcês S; Demengeot J
    Curr Probl Dermatol; 2018; 53():37-48. PubMed ID: 29131036
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Method validation of a bridging immunoassay in combination with acid-dissociation and bead treatment for detection of anti-drug antibody.
    Du J; Yang Y; Zhu L; Wang S; Yu C; Liu C; Long C; Chen B; Xu G; Zou L; Wang L
    Heliyon; 2023 Mar; 9(3):e13999. PubMed ID: 36915535
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab.
    Gorovits B; Baltrukonis DJ; Bhattacharya I; Birchler MA; Finco D; Sikkema D; Vincent MS; Lula S; Marshall L; Hickling TP
    Clin Exp Immunol; 2018 Jun; 192(3):348-365. PubMed ID: 29431871
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-drug antibodies anti-trastuzumab in the treatment of breast cancer.
    Padrón IM; García JG; Díaz RR; Lenza IC; Nicolás FG
    J Oncol Pharm Pract; 2021 Sep; 27(6):1354-1356. PubMed ID: 32873135
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products.
    Shankar G; Devanarayan V; Amaravadi L; Barrett YC; Bowsher R; Finco-Kent D; Fiscella M; Gorovits B; Kirschner S; Moxness M; Parish T; Quarmby V; Smith H; Smith W; Zuckerman LA; Koren E
    J Pharm Biomed Anal; 2008 Dec; 48(5):1267-81. PubMed ID: 18993008
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity of golimumab and its clinical relevance in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
    Leu JH; Adedokun OJ; Gargano C; Hsia EC; Xu Z; Shankar G
    Rheumatology (Oxford); 2019 Mar; 58(3):441-446. PubMed ID: 30412238
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential effect of drug interference in immunogenicity assays.
    Hart MH; de Vrieze H; Wouters D; Wolbink GJ; Killestein J; de Groot ER; Aarden LA; Rispens T
    J Immunol Methods; 2011 Sep; 372(1-2):196-203. PubMed ID: 21824477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mitigating target interference in bridging immunogenicity assay with target-blocking reagents and mild basic pH.
    Chen J; Garlits J; Dhulipala G; Sirimanne T; Xu C; Lu K; Palackal N; Pyles E; Torri A; Sumner G
    Bioanalysis; 2019 Sep; 11(17):1569-1580. PubMed ID: 31208197
    [No Abstract]   [Full Text] [Related]  

  • 29. Novel drug and soluble target tolerant antidrug antibody assay for therapeutic antibodies bearing the P329G mutation.
    Wessels U; Schick E; Ritter M; Kowalewsky F; Heinrich J; Stubenrauch K
    Bioanalysis; 2017 Jun; 9(11):849-859. PubMed ID: 28517957
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immuno-PCR assays for immunogenicity testing.
    Spengler M; Adler M; Jonas A; Niemeyer CM
    Biochem Biophys Res Commun; 2009 Sep; 387(2):278-82. PubMed ID: 19577544
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-drug Antibody Assay Validation: Improved Reporting of the Assay Selectivity via Simpler Positive Control Recovery Data Analysis.
    Gorovits B; Roldan MA; Baltrukonis D; Cai CH; Donley J; Jani D; Kamerud J; McCush F; Thomas JS; Wang Y
    AAPS J; 2019 Jun; 21(5):76. PubMed ID: 31214862
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Understanding the Supersensitive Anti-Drug Antibody Assay: Unexpected High Anti-Drug Antibody Incidence and Its Clinical Relevance.
    Song S; Yang L; Trepicchio WL; Wyant T
    J Immunol Res; 2016; 2016():3072586. PubMed ID: 27340678
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An immunoinhibition approach to overcome the impact of pre-existing antibodies on cut point establishment for immunogenicity assessment of moxetumomab pasudotox.
    Schneider AK; Vainshtein I; Roskos LK; Chavez C; Sun B; Liang M
    J Immunol Methods; 2016 Aug; 435():68-76. PubMed ID: 27220271
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of antibodies against therapeutic proteins in the presence of residual therapeutic protein using a solid-phase extraction with acid dissociation (SPEAD) sample treatment prior to ELISA.
    Smith HW; Butterfield A; Sun D
    Regul Toxicol Pharmacol; 2007 Dec; 49(3):230-7. PubMed ID: 17869396
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of a novel homogeneous immunoassay using the engineered luminescent enzyme NanoLuc for the quantification of the mycotoxin fumonisin B1.
    Alsulami T; Nath N; Flemming R; Wang H; Zhou W; Yu JH
    Biosens Bioelectron; 2021 Apr; 177():112939. PubMed ID: 33440308
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Solution ELISA as a platform of choice for development of robust, drug tolerant immunogenicity assays in support of drug development.
    Mikulskis A; Yeung D; Subramanyam M; Amaravadi L
    J Immunol Methods; 2011 Feb; 365(1-2):38-49. PubMed ID: 21130095
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity testing of therapeutic antibodies in ocular fluids after intravitreal injection.
    Wessels U; Zadak M; Reiser A; Brockhaus J; Ritter M; Abdolzade-Bavil A; Heinrich J; Stubenrauch K
    Bioanalysis; 2018 Jun; 10(11):803-814. PubMed ID: 29637799
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug Tolerant Anti-drug Antibody Assay for Infliximab Treatment in Clinical Practice Identifies Positive Cases Earlier.
    Kharlamova N; Hermanrud C; Dunn N; Ryner M; Hambardzumyan K; Vivar Pomiano N; Marits P; Gjertsson I; Saevarsdottir S; Pullerits R; Fogdell-Hahn A
    Front Immunol; 2020; 11():1365. PubMed ID: 32793189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity screening assay development for a novel human-mouse chimeric anti-CD147 monoclonal antibody (Metuzumab).
    Mi L; Li W; Li M; Chen T; Wang M; Sun L; Chen Z
    J Immunol Methods; 2016 Jun; 433():38-43. PubMed ID: 26944771
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of different immunoassay methods to detect human anti-drug antibody using the WHO erythropoietin antibody reference panel for analytes.
    Shibata H; Nishimura K; Miyama C; Tada M; Suzuki T; Saito Y; Ishii-Watabe A
    J Immunol Methods; 2018 Jan; 452():73-77. PubMed ID: 28970009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.